Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2004-07-16
2010-12-21
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S171000, C514S182000
Reexamination Certificate
active
07855190
ABSTRACT:
The present invention provides contraceptive regimens in which a female is administered a combined dosage form of estrogen and progestin followed by a period of administration of estrogen. The disclosed contraceptive regimens can be administered to a female as a method of providing non-contraceptive benefits.
REFERENCES:
patent: 3568828 (1971-03-01), Lerner
patent: 4145416 (1979-03-01), Lachnit-Fixson et al.
patent: 4171358 (1979-10-01), Black
patent: 4215691 (1980-08-01), Wong
patent: 4291014 (1981-09-01), Keith et al.
patent: 4292315 (1981-09-01), Vorys
patent: 4390531 (1983-06-01), Edgren
patent: 4438139 (1984-03-01), Keith et al.
patent: 4530839 (1985-07-01), Pasquale
patent: 4534468 (1985-08-01), Nuckols et al.
patent: 4544554 (1985-10-01), Pasquale
patent: 4616006 (1986-10-01), Pasquale
patent: 4628051 (1986-12-01), Pasquale
patent: 4685911 (1987-08-01), Konno et al.
patent: 4736849 (1988-04-01), Leonard et al.
patent: 4752478 (1988-06-01), Bondi et al.
patent: 4762717 (1988-08-01), Crowley, Jr.
patent: 4962098 (1990-10-01), Boissonneault
patent: 4971998 (1990-11-01), Wurtman et al.
patent: 4994449 (1991-02-01), Leonard
patent: 5010070 (1991-04-01), Boissonneault
patent: 5043331 (1991-08-01), Hirvonen et al.
patent: 5098714 (1992-03-01), Wright et al.
patent: 5108995 (1992-04-01), Casper
patent: 5208225 (1993-05-01), Boissonneault et al.
patent: 5256421 (1993-10-01), Casper
patent: 5262408 (1993-11-01), Bergink
patent: 5276022 (1994-01-01), Casper
patent: 5280023 (1994-01-01), Ehrlich et al.
patent: 5296230 (1994-03-01), Chien et al.
patent: 5340584 (1994-08-01), Spicer et al.
patent: 5382573 (1995-01-01), Casper
patent: 5510341 (1996-04-01), Ehrlich et al.
patent: 5552394 (1996-09-01), Hodgen
patent: 5567695 (1996-10-01), Labrie
patent: 5585370 (1996-12-01), Casper
patent: 5633242 (1997-05-01), Oettel et al.
patent: 5662927 (1997-09-01), Ehrlich et al.
patent: RE35724 (1998-02-01), Pasquale
patent: 5747480 (1998-05-01), Gast
patent: 5753639 (1998-05-01), Labrie
patent: 5756490 (1998-05-01), Lachnit et al.
patent: 5827843 (1998-10-01), Koninckx
patent: 5858405 (1999-01-01), Gast
patent: 5891867 (1999-04-01), Lanquetin et al.
patent: 5898032 (1999-04-01), Hodgen
patent: RE36247 (1999-07-01), Plunkett et al.
patent: 5980940 (1999-11-01), Spona et al.
patent: 6027749 (2000-02-01), Schmidt-Gollwitzer et al.
patent: 6028064 (2000-02-01), Rodriguez et al.
patent: 6139873 (2000-10-01), Hughes, Jr. et al.
patent: 6214815 (2001-04-01), Shangold et al.
patent: 6251956 (2001-06-01), Kafrissen et al.
patent: 6265393 (2001-07-01), Heinrichs
patent: 6306914 (2001-10-01), de Ziegler et al.
patent: 6312722 (2001-11-01), Schmidt-Gollwitzer et al.
patent: 6319911 (2001-11-01), Rodriguez
patent: RE37838 (2002-09-01), Spona et al.
patent: 6451779 (2002-09-01), Hesch
patent: 6479475 (2002-11-01), Gast
patent: 6500814 (2002-12-01), Hesch
patent: 6511970 (2003-01-01), Rodriguez
patent: 6765002 (2004-07-01), Rodriguez
patent: 6787531 (2004-09-01), Hilman et al.
patent: 7150355 (2006-12-01), Coe et al.
patent: 7320969 (2008-01-01), Bell et al.
patent: 7427609 (2008-09-01), Leonard
patent: 2001/0044431 (2001-11-01), Rodriguez
patent: 2002/0132801 (2002-09-01), Heil et al.
patent: 2003/0018018 (2003-01-01), Hodgen et al.
patent: 2003/0114429 (2003-06-01), Hilman et al.
patent: 2003/0119798 (2003-06-01), Heil et al.
patent: 2003/0139381 (2003-07-01), Bell et al.
patent: 2003/0144258 (2003-07-01), Heil et al.
patent: 2003/0216366 (2003-11-01), Leonard et al.
patent: 2003/0229057 (2003-12-01), Caubel et al.
patent: 2004/0009960 (2004-01-01), Heil et al.
patent: 2004/0142914 (2004-07-01), Friedman et al.
patent: 2004/0222123 (2004-11-01), Niemann
patent: 2004/0251301 (2004-12-01), Niemann et al.
patent: 2005/0064031 (2005-03-01), Stockemann et al.
patent: 2006/0135496 (2006-06-01), DiLiberti et al.
patent: 2007/0111975 (2007-05-01), DiLiberti et al.
patent: 2007/0158233 (2007-07-01), Coe et al.
patent: 2008/0064670 (2008-03-01), Bell et al.
patent: 2008/0125402 (2008-05-01), DiLiberti et al.
patent: 2008/0132473 (2008-06-01), Bell et al.
patent: 1189101 (1998-07-01), None
patent: 0 253 607 (1988-01-01), None
patent: 0 911 029 (2002-04-01), None
patent: WO 93/17686 (1993-09-01), None
patent: WO 98/04246 (1998-02-01), None
patent: WO 98/04266 (1998-02-01), None
patent: WO 98/04267 (1998-02-01), None
patent: WO 00/38691 (2000-07-01), None
patent: WO 01/93848 (2001-12-01), None
patent: WO 02/03975 (2002-01-01), None
patent: WO 03/049744 (2003-06-01), None
patent: WO 2004/080442 (2004-09-01), None
patent: WO 2005/032558 (2005-04-01), None
British Medical Journal, Nov. 1969, pp. 380-381.
European Opposition Document D32, Facts About Seasonale®, 1 page, Barr Laboratories, Inc. (available after Sep. 5, 2003), cited in the Opposition to Patent No. 0 911 029 B1.
European Opposition Document D33, Seasonale® Product Brochure, 15 pages, Duramed Pharmaceuticals, Inc. (Jan. 2004), cited in the Opposition to Patent No. 0 911 029 B1.
Goldzieher, J.W., “Use and Misuse of the Term Potency with Respect to Oral Contraceptives,”J. Reprod. Med. 31: 533-539, The Journal of Reproductive Medicine, Inc. (1986).
King, R.J.B. and Whitehead, M.I., “Assessment of the potency of orally administered progestins in women,”Fertility and Sterility46: 1062-1066, The American Fertility Society (1986).
Mashchak, C.A., et al., “Comparison of pharmacodynamic properties of various estrogen formulations,”Am. J. Obstet. Gynecol. 144: 511-518, The C.V. Mosby Company (1982).
Miller, L. and Notter, K., “Menstrual Reduction With Extended Use of Combination Oral Contraceptive Pills: Randomized Controlled Trial,”Obstet. Gynecol. 98: 771-778, Elsevier Science, Inc. (2001).
Phillips, A., et al., “A Comparison of the Potencies and Activities of Progestogens Used in Contraceptives,”Contraception36: 181-192, Geron-X, Inc. (1987).
Piper, J.M. and Kennedy, D.L., “Oral Contraceptives in the United States: Trends in Content and Potency,”Intl. J. of Epidemiol. 16: 215-221, Oxford University Press (1987).
Shearman, R.P., “Oral contraceptive agents,”Med. J. Australia144: 201-205, Australasian Medical Publishing Company (1986).
“Headaches: OCs are ‘guilty by association’,”Contraceptive Technology Update14:109-112, Thomson American Health Consultants (1993).
International Search Report for International Application No. PCT/US02/38602, European Patent Office, Netherlands, mailed on Apr. 4, 2003.
Co-pending U.S. Appl. No. 10/893,795, inventor Hodgen, G.D., filed Jul. 19, 2004, entitled “Methods of Extended Use Oral Contraception” (as amended) (Not Published).
Kistner, R.W., “The Treatment of Endometriosis by Inducing Pseudopregnancy with Ovarian Hormones,”Fertil. Steril. 10:539-556, Paul B. Hoeber, Inc. Publishers (1959).
Kistner, R.W., “The Effects of New Synthetic Progestogens on Endometriosis in the Human Female,”Fertil. Steril. 16:61-80, Harper & Row, Publishers, Inc. (1965).
Kistner, R.W., “Current Status of the Hormonal Treatment of Endometriosis,”Clin. Obstet. Gynecol. 9:271-292, Harper & Row, Publishers, Inc. (1966).
Kistner, R.W., “Management of Endometriosis in the Infertile Patient,”Fertil. Steril. 26:1151-1166, Harper & Row, Publishers, Inc. (1975).
Rumore, M.M., and Rumore, J.S., “Clinical Therapeutics of Endometriosis, Part 2,”Am. Pharm. NS29:40-44, American Pharmaceutical Association (1989).
International Search Report for International Application No. PCT/US04/22829, United States Patent and Trademark Office, United States, mailed on Oct. 16, 2006.
American Psychiatric Association, “Premenstrual Dysphoric Disorder,” inDSM-IV™: Diagnostic and Statistical Manual of Mental Disorders, 4thEd., American Psychiatric Association, Washington, DC, pp. 715-718 (1994).
Anderson, F.D., “The Safety and Efficacy of Seasonale, a Novel 91-Day Extended Oral Contraceptive Regimen,”Obstet. Gynecol. 99:26S
Bell Robert G.
Ben-Maimon Carole S.
Bronnenkant Lance J.
Hait Howard
Iskold Beata
Jean-Louis Samira
Padmanabhan Sreeni
Sterne Kessler Goldstein & Fox P.L.L.C.
Teva Women's Health, Inc.
LandOfFree
Methods of hormonal treatment utilizing contraceptive... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of hormonal treatment utilizing contraceptive..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of hormonal treatment utilizing contraceptive... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4236446